Role of Serotonin and Noradrenaline in the Rapid Antidepressant Action of Ketamine
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Depression is a chronic and debilitating illness that interferes severely with many human behaviors, and is the leading cause of disability in the world. There is data suggesting that deficits in serotonin neurotransmission can contribute to the development of depression. Indeed, >90% of prescribed antidepressant drugs act by increasing serotonergic transmission at the synapse. However, this increase is offset by a negative feedback operating at the level of the cell body of the serotonin neurons in the raphe nuclei. In the present work, we demonstrate: first, the intracortical infusion of ketamine induced an antidepressant-like effect in the forced swim test, comparable to that produced by systemic ketamine; second, systemic and intracortical ketamine increased serotonin and noradrenaline efflux in the prefrontal cortex, but not in the dorsal raphe nucleus; third, systemic and intracortical administration of ketamine increased the efflux of glutamate in the prefrontal cortex and dorsal raphe nucleus; fourth, systemic ketamine did not alter the functionality of 5-HT1A receptors in the dorsal raphe nucleus. Taken together, these findings suggest that the antidepressant-like effects of ketamine are caused by the stimulation of the prefrontal projection to the dorsal raphe nucleus and locus coeruleus caused by an elevated glutamate in the medial prefrontal cortex, which would stimulate release of serotonin and noradrenaline in the same area. The impact of both monoamines in the antidepressant response to ketamine seems to have different time frames.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another microdialysis study observed increases in extracellular serotonin and norepinephrine in the mPFC but not in the DRN of rats two hours following treatment with ketamine (25 mg/kg, i.p.) (López-Gil et al., 2019).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as López-Gil et al., 2019
In the citing paper
“Reverse dialysis of ketamine (300 μM, 1 μL/min) into the mPFC over a span of two hours replicated the increases in norepinephrine, serotonin, and glutamate in the mPFC but also produced an increase in glutamate within the DRN.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as López-Gil et al., 2019
In the citing paper
“Extracellular glutamate was also increased in the mPFC and the DRN two hours post-ketamine.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as López-Gil et al., 2019
Citations
Cites
The Rat Brain in Stereotaxic Coordinates
(1982) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 51,963
The rat brain in stereotaxic coordinates
Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,831
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Cryan, J. F., Valentino, R. J., & Lucki, I. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.008 · Cited by 1,119
Current advances and trends in the treatment of depression
Blier, P., & de Montigny, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90315-8 · Cited by 1,113
Cited by
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Brain NMDA Receptors in Schizophrenia and Depression
Adell, A. (2020) · Biomolecules · doi:10.3390/biom10060947 · Cited by 212
Self-citationMechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Yan, H., Wang, Y., Huo, F., & Yin, C. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c13223 · Cited by 142
Ketamine: Mechanisms and Relevance to Treatment of Depression
Kim, J., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-051322-120608 · Cited by 147
Tiger, M., Veldman, E. R., Ekman, C.-J., Halldin, C., Svenningsson, P., & Lundberg, J. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0844-4 · Cited by 81
Murphy, G. S., Avram, M. J., Greenberg, S. B., Benson, J., Bilimoria, S. N., Maher, C. E., Teister, K. J., & Szokol, J. W. (2021) · Anesthesiology · doi:10.1097/aln.0000000000003743 · Cited by 82
“Like methadone, ketamine inhibits the NMDA receptor,(26) binds to the μ-opioid receptor,(27) and increases concentrations of serotonin and norepinephrine in the brain.(28) The use of ketamine in the setting of spinal fusion surgery has been extensively studied.”
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
The role of serotonin in depression—A historical roundup and future directions
Bremshey, S., Groß, J., Renken, K., & Masseck, O. A. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16097 · Cited by 69
Chen, T., Cheng, L., Ma, J., Yuan, J., Pi, C., Xiong, L., Chen, J., Liu, H., Tang, J., Zhong, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106837 · Cited by 52
Response Flexibility: The Role of the Lateral Habenula
Hones, V. I., & Mizumori, S. J. Y. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.852235 · Cited by 44
“Ketamine, a common antidepressant medication, has been shown to elevate raphe activity in addition to decreasing the hyperactivity of the LHb, consistent with the role of this pathway in depression (Cui et al., 2018; Yang et al., 2018; López-Gil et al., 2019).”
Ketamine: The final frontier or another depressing end?
Sial, O. K., Parise, E. M., Parise, L. F., Gnecco, T., & Bolaños‐Guzmán, C. A. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112508 · Cited by 43
“Systemic administration of sub-anesthetic antidepressant doses of ketamine (10 or 25mg/kg) in rats did not increase NE in the DRN, but significantly increased NE in the mPFC at the 25 mg/kg dose [208].”
BackgroundVecchia, D. D., Kanazawa, L. K. S., Wendler, E., Hocayen, P. D. A. S., Vital, M. A. B. F., Takahashi, R. N., Cunha, C. D., Miyoshi, E., & Andreatini, R. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.12.011 · Cited by 39
“Interestingly, systemic ketamine administration increased 5-HT and NA efflux in the prefrontal cortex (López-Gil et al., 2019).”
BackgroundBowman, M. A., Vitela, M., Clarke, K. M., Koek, W., & Daws, L. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207581 · Cited by 33
Elshikh, M. S., Chen, T.-W., Govindasamy, M., Chen, S., Huang, P.-J., Ali, M. A., Al-Hemaid, F. M. A., & Al-Mohaimeed, A. M. (2020) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2020.105305 · Cited by 33
Duque, M., Chen, A., Hsu, E. T., Narayan, S., Rymbek, A., Begum, S., Saher, G., Cohen, A. E., Olson, D. E., Li, Y., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.11.011 · Cited by 34
Pham, T. H., Defaix, C., Nguyen, T. M. L., Mendez‐David, I., Tritschler, L., David, D. J. P., & Gardier, A. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172913 · Cited by 30
Iro, C. M., Hamati, R., Mansari, M. E., & Blier, P. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab010 · Cited by 31
Lin, X., Feng, X., Sun, L., Wang, Y., Wu, X., Lu, S., Shao, L., Wang, W., Yang, L., Geng, W., et al. (2024) · BMC Anesthesiology · doi:10.1186/s12871-024-02513-w · Cited by 30
“Esketamine, an NMDA receptor antagonist similar to ketamine, exhibits binding affinity to opiate receptors and modulates serotonin and norepinephrine levels in the brain, thereby exerting analgesic, anti-inflammatory, and neuroprotective effects [30].”
BackgroundVines, L., Sotelo, D., Johnson, A., Dennis, E., Manza, P., Volkow, N. D., & Wang, G. (2022) · Intelligent Medicine · doi:10.1016/j.imed.2022.03.001 · Cited by 27
Tarrés-Gatius, M., Miquel-Rio, L., Campa, L., Artigas, F., & Castañé, A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01110-y · Cited by 29
Self-citationSublingual AKBA Exerts Antidepressant Effects in the Aβ-Treated Mouse Model
Morgese, M. G., Bové, M., Francavilla, M., Schiavone, S., Dimonte, S., Colia, A. L., Bevilacqua, M., Trabace, L., & Tucci, P. (2021) · Biomolecules · doi:10.3390/biom11050686 · Cited by 29
“mechanisms underlying the antidepressant activity of ketamine [50].”
BackgroundRoles of the monoaminergic system in the antidepressant effects of ketamine and its metabolites
Ago, Y., Yokoyama, R., Asano, S., & Hashimoto, H. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109313 · Cited by 26
Ketamine and sleep modulate neural complexity dynamics in cats
Pascovich, C., Castro‐Zaballa, S., Mediano, P. A. M., Bor, D., Canales‐Johnson, A., Torterolo, P., & Bekinschtein, T. A. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15646 · Cited by 21
“Previous work reported that subanesthetic doses of ketamine increased the release of not only 5-HT (Amargós-Bosch et al., 2006; López-Gil et al., 2012, 2019), but also noradrenaline (Lorrain et al., 2003) as well as glutamate (Moghaddam et al., 1997) in the medial prefrontal cortex, which may…”
BackgroundSerotonin is a common thread linking different classes of antidepressants
Witt, C. E., Mena, S., Holmes, J., Hersey, M., Buchanan, A. M., Parke, B., Saylor, R., Honan, L. E., Berger, S. N., Lumbreras, S., et al. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.10.009 · Cited by 18
A Computational Model of Hopelessness and Active-Escape Bias in Suicidality
Karvelis, P., & Diaconescu, A. O. (2022) · Computational Psychiatry · doi:10.5334/cpsy.80 · Cited by 19
Li, D., Pan, Q., Xiao, Y., & Hu, K. (2024) · Schizophrenia · doi:10.1038/s41537-024-00485-x · Cited by 19
“Abnormally excited hippocampal neurons may directly or indirectly activate dopaminergic and 5-HT neurons in the midbrain and enhanced release of monoamine transmitters 66,67 , which involving in mediating the PCP-induced SZ-like symptoms.”
BackgroundDelcourte, S., Etiévant, A., & Haddjeri, N. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.002 · Cited by 18
Carboni, E., & Carta, A. R. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2105144 · Cited by 17
Cabanu, S., Pilar-Cuéllar, F., Zubakina, P., Florensa-Zanuy, E., Senserrich, J., Newman‐Tancredi, A., & Adell, A. (2022) · Pharmaceuticals · doi:10.3390/ph15030337 · Cited by 16
Self-citationRiggs, L. M., Thompson, S. M., & Gould, T. D. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109153 · Cited by 16
Li, T., Han, L., Wu, Z., Chen, Y., & Wang, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s513571 · Cited by 13
Daniels, S., Mansari, M. E., Hamoudeh, R. A., & Blier, P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1276309 · Cited by 12
Wang, Y., Zhang, Y., Wang, K., Zhu, Z., Wang, D., Yang, Q., & Dong, H. (2022) · Journal of Neurophysiology · doi:10.1152/jn.00462.2021 · Cited by 12
Opioids Safety in Pediatric Procedural Sedation with Ketamine
Cohen, N., Test, G., Pasternak, Y., Singer‐Harel, D., Schneeweiss, S., Ratnapalan, S., Schuh, S., & Finkelstein, Y. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.11.072 · Cited by 13
Colla, M., Scheerer, H., Weidt, S., Seifritz, E., & Kronenberg, G. (2021) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2021.759466 · Cited by 12
Elwyn, R., Mitchell, J., Kohn, M. R., Driver, C., Hay, P., Lagopoulos, J., & Hermens, D. F. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105122 · Cited by 11
Modulation of the endocannabinoid system by (S)-ketamine in an animal model of depression
da Silva, N. R., Arjmand, S., Domingos, L. B., Filho, A. J. M. C., Mottin, M., Real, C. C., Waszkiewicz, A., Gobira, P. H., Ferraro, A. N., Landau, A. M., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107545 · Cited by 9
Wang, Y., Xu, J., Zhou, X., Che, L., Qiu, M., Liu, Y., Gao, M., & Yang, Z. (2025) · Advanced Science · doi:10.1002/advs.202516024 · Cited by 13
Suicide prevention and ketamine: insights from computational modeling
Charlton, C. E., Karvelis, P., McIntyre, R. S., & Diaconescu, A. O. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1214018 · Cited by 7
Warner, A. K., Iskander, L., Allen, K., Quatela, I., Borrelli, H., & Sachs, B. D. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110082 · Cited by 7
Silva-Cardoso, G. K., & Nobre, M. J. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03300-6 · Cited by 6
Pascual-Antón, R., Blasco‐Serra, A., Muñoz‐Moreno, E., Pilar-Cuéllar, F., Garro-Martínez, E., Florensa-Zanuy, E., López-Gil, X., Campa, V. M., Sòria, G., & Adell, A. (2021) · Brain Structure and Function · doi:10.1007/s00429-021-02354-0 · Cited by 6
Self-citationMarti, M., Talani, G., Miliano, C., Bilel, S., Biggio, F., Bratzu, J., Diana, M., Luca, M. A. D., & Fattore, L. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113836 · Cited by 6
Rech, T. D. S. T., Strelow, D. N., Krüger, L. D., Neto, J. S. S., Blödorn, G. B., Alves, D. A. C., Brüning, C. A., & Bortolatto, C. F. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02508-3 · Cited by 6
“…for example, appear to be related to the prefrontal projection stimulation to the dorsal nucleus of the raphe and locus coeruleus that is caused by a glutamate elevation in the medial prefrontal cortex region, and this stimulates the serotonin and noradrenaline release (Lopez-Gil et al. 2019).”
Deka, A., Joseph, E., Sharma, N., Berhanu, T., & Kaplan, J. (2024) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000787 · Cited by 5
“In 2019, Lopez et al 30 proposed a pathway for ketamine ’ s antidepressant action that included downstream effects of increased glutamate in the medial prefrontal cortex, leading to stimulation of the prefrontal projection to the dorsal raphe nucleus and locus coeruleus.”
Background5-HT1B receptor activation produces rapid antidepressant-like effects in rodents
Clark, E. A., Wang, L., Hanania, T., Kretschmannova, K., Bianchi, M., Jagger, E., Hu, T., Li, F., Gallero-Salas, Y., Koblan, K. S., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173917 · Cited by 5
Anderson, T. L., Asadipooya, A., & Ortinski, P. I. (2025) · eNeuro · doi:10.1523/eneuro.0047-25.2025 · Cited by 4
“Furthermore, ketamine increases extracellular 5-HT in the prefrontal cortex (Lopez-Gil et al., 2019), and 5-HT depletion blocks the antidepressant effects of ( S )-ketamine (du Jardin et al., 2017), highlighting a potential role of serotonergic signaling in the effects of rapid-acting…”
Martinez, M. R., Garmon, E. H., Starling, G. D., & Sheth, M. A. (2022) · Ochsner Journal · doi:10.31486/toj.22.0011 · Cited by 4
Drozd, U. S., Lanshakov, D. A., & Дыгало, Н. Н. (2023) · Neurochemical Journal · doi:10.1134/s181971242303008x · Cited by 4
Yang, X., Wu, X., Qin, B., Wang, Z., Zhu, X., & Huang, S. (2022) · Cellular and Molecular Biology · doi:10.14715/cmb/2022.68.2.13 · Cited by 4
“In this study, the incidence of agitation during the awakening period was significantly lower in the observation group than in the control group, in keeping with the results reported in the references that ketamine triggers psychiatric symptoms such as hallucinations, nightmares, delirium and restlessness during the r…”
ResultZaccarelli‐Magalhães, J., Abreu, G. R., Fukushima, A. R., Pantaleon, L. D. P., Ribeiro, B. B., Munhoz, C., Manes, M., de Lima, M. A., Miglioli, J., Flório, J. C., et al. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114799 · Cited by 3
Research Progress on the Mechanism of Ketamine in Neuropathic Pain Comorbid Depression
Li, Q., Liu, S., Qin, B., & Liu, X. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s534938 · Cited by 3
“Research 71 suggests that the antidepressant effect of ketamine is due to the increase of glutamate in the medial prefrontal cortex, which stimulates the projection of the prefrontal lobe to the medial dorsal nucleus and locus coeruleus, thereby stimulating the release of serotonin and…”
Yu, X., Pang, P., Liu, T., Jiang, X., Zhang, J., Yue, X., Guo, J., Cheng, X., Zhao, T., Zhao, Y., et al. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.08.013 · Cited by 3
Contreras, C. M., & Gutiérrez‐García, A. G. (2024) · Neuroscience Letters · doi:10.1016/j.neulet.2024.137848 · Cited by 3
Valentino, K., Ballum, H., Cheung, W., Dri, C. E., Teopiz, K. M., Kwan, A. T. H., Wong, S., Shen, B., Cheng, M. C. H., Le, G. H., et al. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.02.011 · Cited by 2
Depoortère, R., Papp, M., Gruca, P., Litwa, E., Łasoń, M., Biała, D., & Newman‐Tancredi, A. (2024) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000809 · Cited by 2
What value do NMDA receptor antagonist models of schizophrenia have for novel drug discovery?
Adell, A. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2562017 · Cited by 2
“Indeed, NMDA receptor antagonists increased the release of glutamate [84–86], norepinephrine [87,88], dopamine [89–91] and 5-HT [79,85,92,93] in the prefrontal cortex.”
Self-citationBakhtiari, E., Dori, M. M., Razavi, M. R. D., Yazdi, A. S., & Yazdi, A. P. (2024) · Anesthesia and Pain Medicine · doi:10.17085/apm.23129 · Cited by 2
Tonosaki, M., Kushikata, T., Nikaido, Y., Takekawa, D., Kinoshita, H., Saito, J., & Hirota, K. (2025) · Journal of Anesthesia · doi:10.1007/s00540-025-03521-x · Cited by 1
“One possibility is that the reduction in NA activity in TG rats may have weakened the sedative effects of ketamine, as the activation of central NA is required to exert the sedative effects of ketamine [10, 13, 22, 23].”
Mechanism of antidepressant action of ketamine and differences between its two enantiomers
Zhan, J., Zhang, Y., Tian, H., Zhu, X., Guo, M., Qiu, Z., & Xia, Z. (2025) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2025.06.001 · Cited by 1
Chaïb, S., Levigoureux, E., Bouvard, S., Bouillot, C., Vidal, B., Fourier, A., Newman‐Tancredi, A., & Zimmer, L. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03572-4 · Cited by 1
“As a leading RAAD, ketamine has also demonstrated ef fi cacy in modulating the serotonergic system by stimulating the release of 5-HT in the prefrontal cortex and activating post-synaptic 5-HT 1A receptors [7, 8].”
Mageed, S. S. A., Mangoura, S. A., Nassar, N. N., Moawad, H., & Kamel, A. S. E. D. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115681 · Cited by 1
Schizophrenia Pathophysiology: Neurotransmitter Dysfunctions and Biomarker Frontiers
Balkrishna, A., Singh, S. K., Verma, S., Bora, P., Dobhal, V., & Arya, V. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266389476250818112814 · Cited by 1
Sales, A. J., Fronza, M. G., Pedrazzi, J. F. C., Lisboa, S. F. D. S., & Guimarães, F. S. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116229 · Cited by 1
AMPA Receptor Potentiators as Potential Rapid-Acting Antidepressants
Garro-Martínez, E., & Adell, A. (2021) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-79790-4_6 · Cited by 1
Self-citationIro, C. M. (2019) · uO Research (University of Ottawa) · doi:10.20381/ruor-24149
“Additionally, we examined dorsal raphe nucleus (DRN) serotonin (5-HT) neurons to assess the effects of single and repeated ketamine administration on these neurons.”
BackgroundInfluentialTarrés-Gatius, M. (2019) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · Cited by 1
Zanuy, F., & Ariadna, E. (2021) · UCrea (University of Cantabria) · Cited by 1
Incrocci, R. M. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.59.2023.tde-04102023-070350
Drozd, U. S., Lanshakov, D. A., & Дыгало, Н. Н. (2023) · Нейрохимия · doi:10.31857/s1027813323030081
Chaïb, S. (2023) · theses.fr (ABES) · doi:10.70675/00e3b294z3b0az4a32zb1c5z3c09edd92416 · Cited by 1
Ketamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Es-Safi, S., Bourcier‐Lucas, C., Abrial, E., Cathala, A., Lesté-Lasserre, T., Deurwaerdère, P. D., Revest, J., Mazella, J., Haddjeri, N., & Lucas, G. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.24.684353
“Several reports have shown that subanaesthetic doses of ketamine may increase the release of 5-HT within minutes post-administration in the mPFC of both rats and mice (20,26,48-52).”
Influential(IIBB), C.-I. D. I. B. D. B. (2021) · DIGITAL.CSIC (Spanish National Research Council (CSIC)) · doi:10.20350/digitalcsic/13681
Miller, C. O. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-13315-1_2
Pantoja, L. V. P. D. S., Soares, L. F. R., da Conceição, B. C., Carvalheiro-Simas, T. C. V. S., Luz, D. A., Prediger, R. D., de Andrade, G. M., Fontes-Júnior, E. A., Pinheiro, B. G., Cartágenes, S. D. C., et al. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116048
Ahmed, A., Mansari, M. E., & Blier, P. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811251405691
Chan-Monroy, J. M., Estrada-Camarena, E. M., & López‐Rubalcava, C. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178705
Ketamine for Bipolar Depression
Fancy, F. (2024) · TSpace (University of Toronto)
Rosenblat, J. D. (2020) · TSpace (University of Toronto)
Tan, W., Gao, Y., Su, D., Ji, L., & Wang, S. W. (2026) · BMC Anesthesiology · doi:10.1186/s12871-026-03839-3
“It is plausible that esketamine could potentiate glutamatergic projections from the prefrontal cortex to the dorsal raphe nucleus, which might subsequently lead to activation of 5-HT neurons and potentially promote 5-HT release [2, 12].”
Qasim, R., Mehmood, H., Raza, M., Tariq, Z., Mohib, K., Haseeb, B., Ahmed, A.-B., Hussain, A. A., Shakeel, I., Aminpoor, H., et al. (2026) · European Journal of Anaesthesiology Intensive Care · doi:10.1097/ea9.0000000000000103
Matheson, G. J., Lundberg, J., Gärde, M., Veldman, E. R., Tateno, A., Ekman, C., Arakawa, R., Knudsen, G. M., Okubo, Y., Ogden, R. T., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03704-2
Singh, B., MahmoudianDehkordi, S., Voort, J. L. V., Parikh, S. V., Achtyes, E. D., Goes, F. S., Bobo, W. V., Greden, J. F., Scaini, G., Tye, S. J., et al. (2026) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2026.2724510 · Cited by 1
Flexibility & Adaptability: The Role of the Lateral Habenula & Medial Prefrontal Cortex
Hones, V. I. (2026) · ResearchWorks at the University of Washington (University of Washington)
Morena, D., Lippi, M., Biso, L., Lucci, F., Turillazzi, E., Fineschi, V., & Scognamiglio, P. (2026) · Clinical Drug Investigation · doi:10.1007/s40261-026-01599-z
Metadata
- Authors
- López-Gil, X., Jiménez-Sánchez, L., Campa, L., Castro, E., Frago, C., & Adell, A.
- Affiliations
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) , , ,
- Instituto de Investigaciones Biomédicas de Barcelona, CSIC, IDIBAPS , , ,
- Consejo Superior de Investigaciones Científicas (ES)
- Universidad de Cantabria (ES)
- Corresponding author
- Adell, Albert
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-06-05
- Volume
- 10
- Issue
- 7
- Pages
- 3318-3326
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2948831208
- Cited by
- 80
- References
- 57
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 11 · 2023: 13 · 2022: 12 · 2021: 12 · 2020: 9
- FWCI
- 5.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- UCrea (University of Cantabria) (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Funders
- European Regional Development Fund
- Centro de Investigación Biomédica en Red de Salud Mental
- Instituto de Salud Carlos III (PI13/00038, PI16/00217)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, serotonin, norepinephrine, depression, prefrontal cortex, dorsal raphe nucleus, locus coeruleus, glutamate, serotonin efflux, noradrenaline efflux, 5-HT1A receptor, forced swim test, monoamines
- MeSH terms
- Animals, Antidepressive Agents, Depression, Ketamine, Male, Motor Activity, Norepinephrine, Serotonin, Rats, Wistar, Prefrontal Cortex, Glutamic Acid, Receptor, Serotonin, 5-HT1A, Rats, Serotonergic Neurons, Dorsal Raphe Nucleus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.